Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Research

Executive Summary: Lisinopril dihydrate is a highly specific, long-acting ACE inhibitor with an IC₅₀ of 4.7 nM, suitable for precise modulation of the renin-angiotensin system (Tieku & Hooper 1992, DOI). It decreases angiotensin II and aldosterone levels, inducing vasodilation and blood pressure reduction. The compound is water-soluble (≥2.46 mg/mL with warming/ultrasonication), has a molecular weight of 441.52 g/mol, and a chemical formula C₂₁H₃₅N₃O₇ (APExBIO datasheet, product page). Lisinopril dihydrate is validated by mass spectrometry and NMR, and is recommended for research in hypertension, heart failure, myocardial infarction, and diabetic nephropathy. APExBIO ensures ≥98% purity and robust workflow support for experimental reproducibility.

Biological Rationale

Lisinopril dihydrate targets the renin-angiotensin system, a central pathway in blood pressure regulation and fluid balance. Angiotensin converting enzyme (ACE) catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor that also stimulates aldosterone secretion. Inhibition of ACE leads to reduced angiotensin II and aldosterone, promoting vasodilation and natriuresis. Lisinopril dihydrate, as a lysine analogue of MK 421, directly inhibits ACE activity and is used to model cardiovascular and renal pathophysiology. Its selectivity reduces off-target effects, supporting precise mechanistic experiments (DOI: 10.1016/0006-2952(92)90065-Q).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate binds competitively to the active site of ACE (EC 3.4.15.1), inhibiting the cleavage of angiotensin I to angiotensin II. The IC₅₀ for ACE inhibition is 4.7 nM under standard assay conditions (37°C, pH 8.3 buffer; Tieku & Hooper 1992). This action decreases systemic angiotensin II, resulting in lower vascular resistance and blood pressure. Plasma renin activity increases via feedback stimulation, while aldosterone concentrations decrease. Lisinopril dihydrate exhibits long-acting pharmacodynamics due to slow dissociation from ACE and minimal metabolism, supporting sustained experimental effects in vitro and in vivo. Unlike sulfhydryl-containing ACE inhibitors, lisinopril does not significantly inhibit aminopeptidases A, N, or W, conferring high target specificity (DOI).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE with an IC₅₀ of 4.7 nM in cell-based assays (Tieku & Hooper 1992, DOI).
• The compound demonstrates water solubility ≥2.46 mg/mL with gentle warming and ultrasonication (APExBIO, product page).
• Quality control includes mass spectrometry and NMR confirmation, with ≥98% purity (APExBIO Certificate of Analysis, datasheet).
• Lisinopril dihydrate is effective in models of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy (see Lisinopril Dihydrate in Translational Cardiovascular Research).
• Unlike bestatin and certain sulfhydryl ACE inhibitors, lisinopril shows minimal inhibition of aminopeptidases N, A, and W, reducing confounding effects (Tieku & Hooper 1992, DOI).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely adopted in experimental models of hypertension, providing a robust tool for dissecting the renin-angiotensin system and evaluating antihypertensive therapies. Its validated specificity is particularly valuable for preclinical studies in heart failure, myocardial infarction, and diabetic nephropathy. The compound's reproducible solubility and purity facilitate integration into both in vitro and in vivo workflows. For a detailed comparison of mechanistic and translational strategies, see Lisinopril Dihydrate: Strategic ACE Inhibition for Next-Generation Disease Models. This article extends those findings by providing new benchmarks for target selectivity and solubility under controlled laboratory conditions.

Common Pitfalls or Misconceptions

• Not effective on non-ACE pathways: Lisinopril dihydrate does not inhibit aminopeptidases N, A, or W, and thus is unsuitable for experiments targeting these enzymes (DOI).
• Not soluble in ethanol: The compound is insoluble in ethanol; water is the recommended solvent with gentle warming and ultrasonication (APExBIO).
• Short-term solution stability: Prepared solutions should not be stored long-term; use freshly prepared solutions for optimal activity (APExBIO datasheet).
• No direct antiviral activity: While the renin-angiotensin system is implicated in COVID-19 research, lisinopril dihydrate has no direct antiviral action (Tieku & Hooper 1992).
• Species differences: Pharmacokinetics and pharmacodynamics may differ between rodent and human models; dose adjustments may be required (see Advanced ACE Inhibitor for Hypertension Models for extended discussion).

Workflow Integration & Parameters

Lisinopril dihydrate is provided by APExBIO (SKU: B3290) as a solid compound with a molecular weight of 441.52 g/mol and formula C₂₁H₃₅N₃O₇. For solution preparation, dissolve in water at ≥2.46 mg/mL using gentle warming (≤37°C) and ultrasonic treatment. Store the solid desiccated at room temperature; avoid long-term storage of solutions. Small molecule shipments are sent with blue ice for temperature stability. The compound is supported by Certificate of Analysis and batch-specific QC, including mass spectrometry and NMR. For best practices in experimental design, see Novel Insights into ACE Inhibition, which focuses on advanced workflow integration. This article clarifies the physicochemical and logistical parameters required for robust implementation.

Conclusion & Outlook

Lisinopril dihydrate remains a reference-standard ACE inhibitor for hypertension, heart failure, and nephropathy research. Its high specificity, reproducible solubility, and validated purity support mechanistic, translational, and preclinical workflows. APExBIO's product quality and supporting documentation ensure reproducibility and experimental clarity. Future research may further dissect the selectivity of ACE inhibitors in complex disease models, but Lisinopril dihydrate's well-characterized action and robust support make it a mainstay for renin-angiotensin system studies in both academic and industry settings.